Neutral
●
GlobeNewsWire
●
vor 6 Monaten
MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company's Chief Executive Officer, Stephen Willard, issued the following letter to Longeveron stockholders. Dear Fellow Stockholders, I am delighted to join L...